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 Prognostic and predictive role of topoisomerase alpha 2 and thymidylate synthase expression 
in tumor tissues of patients with adrenocortical carcinoma. 
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Abstract 
 
Topoisomerase II alpha (TOP2A) and Thymidylate Synthase (TS) are known prognostic parameters 
in several tumors. They are also predictors of efficacy of anthracyclines and topoisomerase 
inhibitors and fluoropirimidines, respectively. 
The prognostic and predictive role of tumor tissue mRNA expression of TOP2A and TS was 
assessed in 98 patients with adrenocortical carcinoma (ACC). Ninety-two were radically resected 
for stage II-III disease and 38 of them received adjuvant mitotane after surgery.  Twenty-six 
patients with metastatic disease at first diagnosis  or at the time of recurrence after surgery received 
the EDP-M (Etoposide, Doxorubicin=Adriamycin, Cisplatin plus mitotane). TOP2A and TS 
expression in ACC tissue was directly correlated. Both markers were not associated with either 
disease free survival (DFS) after surgery or overall survival (OS) in multivariate analyses and failed 
to be associated to mitotane efficacy in terms of DFS. A clinical benefit (disease response or disease 
stabilization) to EDP-M treatment was observed in 12/17 (71%) and 1/9 (11%) patients with high 
and low TOP2A expressing tumors (p=0.0039) and 9/13 (69%) and 4/13 (31%) patients with high 
and low TS expressing ACC, respectively (p=0.049). High TOP2A expression was significantly 
associated with longer time to progression after EDP-M. 
TOP2A and TS were neither prognostic nor predictive of mitotane efficacy in ACC patients.   
The predictive role of TOP2A expression of EDP-M activity suggests a significant contribution of 
adriamycin and etoposide for the efficacy of the EDP scheme.  
 
Introduction 
Adrenocortical carcinoma (ACC) is a rare and aggressive malignant tumor [1,2]. Surgery is the 
mainstay of therapy. Although complete surgical removal of ACC is the only potentially curative 
approach, most of the radically resected patients are destined to relapse, often with metastases [3,4]. 
Mitotane is the reference systemic therapy for ACC [5]. On the basis of the results of a large 
retrospective multicentric study carried out at several referral centers in Italy and Germany [6], the 
drug is recommended to be administered in adjuvant setting in radically resected ACC with high 
risk of recurrence [7,8]. The recent finding that mitotane serum levels are prognostic in patients 
receiving the drug as adjuvant therapy provides further evidence in favor of the efficacy of this drug 
in this setting [9]. However, few prognostic factors are currently available to identify the patient 
risk of relapse and death of disease. Currently only disease stage, completeness of initial resection, 
and proliferation index are widely accepted prognostic factors [8,10, 11]. In the patients with 
metastatic disease at diagnosis or showing distant recurrence after surgery, chemotherapy plus 
mitotane is the best treatment strategy. The results of a multinational prospective randomized 
clinical study have established the combination chemotherapy with the topoisomerase II inhibitor 
Etoposide, the anthracycline Doxorubicin, Cisplatin plus mitotane (EDP-M) as the reference 
regimen for this rare disease [12]  Adjuvant mitotane therapy and EDP-M however, are toxic and 
their overall efficacies limited. Therefore, the establishment of predictive factors that identify a 
subset of patients, in whom a certain treatment would be more effective, would be highly desirable.    
We have previously evaluated the expression of ribonucleotide reductase large subunit 1 (RRM1) 
and ERCC1 genes in a multicenter (German and Italian) cohort of ACC patients and provided the 
first evidence in vitro and in vivo that RRM1 gene expression levels are functionally associated to 
mitotane sensitivity and predict response to mitotane treatment in adjuvant setting [13].    
In the same series we assessed the expression of two other biomarkers with potential prognostic 
impact: the topoisomerase II alpha (TOP2A), an enzyme responsible for transcription, replication 
and chromosome condensation and segregation during cell division [14]; and the thymidylate 
synthase (TS), an enzyme involved in nucleotide metabolism [15]. TOP2A is also a well known 
predictor of efficacy of anthracyclines and topoisomerase inhibitors [16] and TS is predictive of the 
efficacy of fluoropyrimidines [17]. In the present study, we explored the prognostic significance of 
these markers in ACC as well as their predictive role for efficacy of adjuvant mitotane and of EDP-
M in patients with advanced disease.   
 
Patients and Methods 
Patients.  
Ninety-eight patients with radically resected ACC between 1989 and 2007 at the San Luigi Hospital 
of Orbassano, University of Turin, Italy (51 patients) and 35 centers in Germany coordinated by the 
German ACC Registry (47 patients) were included according to the following eligibility criteria: 1) 
age of 18 years or older; 2) histologically confirmed diagnosis of ACC after central pathologic 
revision (MV, MP);  3) complete resection of primary ACC, 4) availability of follow-up 
information, 5) availability of representative paraffin-embedded tissue block(s). All patients 
fulfilling these criteria were included in the study. Ninety-two patients were already considered in 
the previously published series that have tested ERCC1 and RRM1 [13]. In the present paper we 
also considered six patients from the Italian archive that were excluded in the published series 
because they were metastatic at diagnosis. These patients were radically resected on primary tumor 
but not on metastatic disease. The diagnosis of ACC was based on the pathological Weiss score 
[18]. Variables recorded included age, sex, hormone secretion, ENSAT stage at diagnosis [19], 
initial therapeutic options including primary surgery, disease-free survival (DFS) for patients 
initially radically resected, defined by the time elapsing from diagnosis to either disease relapse or 
patient death, overall survival (OS), calculated from diagnosis till death, Weiss score, mitotic count, 
sites of metastases at the time of progression. ACC relapse was defined as the appearance of local 
recurrence or metastatic disease at imaging techniques during follow-up. Adjuvant mitotane was 
offered to patients considered at high risk of relapse, in presence of the following criteria: 1) stage 
III ACC; 2) high mitotic index. When a post-operative adjunctive measure was deemed necessary, a 
monitored mitotane treatment aiming at plasma concentrations between 14 and 20 mg/l [20,21] was 
employed. In the absence of intolerability to mitotane, treatment was scheduled for at least 2 years, 
or till ACC recurrence. Follow-up protocols were similar among the different centers including 
imaging (CT or MRI) of both chest and abdomen at baseline and thereafter every 3-6 months until 
disease progression or end of the study period. At each visit, the patients underwent physical 
examination, routine laboratory evaluation and hormonal work-up. Monitoring of mitotane 
concentrations was done in treated patients. For recurrent disease, radical surgery was performed if 
complete resection seemed feasible. In case of not resectable disease, patients received mitotane 
alone or chemotherapy plus mitotane according to disease aggressiveness, tumor bulk and previous 
mitotane exposure. Twenty-six patients, 4 metastatic at diagnosis  and 22 with disease recurrence 
after primary surgery, received the combination of EDP-M. Patients gave informed consent for 
collecting tissue and clinical data and the study was approved by the ethics committees of both 
centres. 
 
RNA isolation from paraffin embedded tissues and quantitative real time PCR.  
Representative tumour areas were dissected under stereomicroscopic assistance from 10 μm 
sections of paraffin-embedded tissue in RNAse-free conditions. RNA isolation was performed by 
commercially available paraffin material RNA extraction kits according to manufacturer’s 
instructions (High Pure RNA Paraffin Kit; Roche Applied Science, Milano, Italy). Complementary 
DNA was transcribed using 500μg/ml oligodT (Roche Applied Science, Penzberg, Germany) and 
500M-MLV RT (200U/μl) (Invitrogen, Carlsbad, California) according to standard protocols. 
Relative cDNA quantification of TS and TOP2A and of internal reference gene (beta-actin) was 
done in duplicate using a fluorescence-based real-time detection method (ABI PRISM 7900 
Sequence Detection System-Taqman; Applied Biosystems, Life Technologies). Primers and probes 
sequences for TS and cycling conditions have already been published elsewhere [21]. TOP2A was 
analyzed using the Mm00495701_g1 assay (Applied Biosystems, Life Technologies). Baseline and 
threshold for cycle (Ct) calculation were set manually with ABI Prism SDS 2.1 Software. A mixture 
containing Human Total RNA (Stratagene, La Jolla, CA) was used as control calibrator on each 
plate. 
The fold change in gene expression levels, expressed in unitless values, was evaluated using the 2
–
ΔΔCt
 method. 
 
Statistical analyses 
Correlation between the expressions of the 2 genes was tested using the Spearman coefficient, 
differences of categorical variables were analyzed using the chi2 test. DFS and OS survival curves 
were computed using the Kaplan–Meier method and compared using the log-rank test. Hazard 
ratios (HR) for disease progression and patient death were estimated using the Cox proportional 
hazard model. Multivariate analyses were carried out adjusting for patient age, sex, Weiss score, 
ACC stage, mitotic count, and cortisol secretion. Cox models were also used to assess the presence 
of heterogeneity in the effect of marker expression in the different patient subgroups, defined by the 
covariates, by including in the model the appropriate treatment/covariate interaction term. Statistical 
analyses were carried out by using the SPSS for windows software (version 17). 
 
Results 
Patients 
Patient characteristics are depicted in Table 1. Both Italian and German cohorts were comparable in 
terms of age, sex proportion, presence of clinical syndromes, and tumor characteristics (data for 92 
patients previously published, [13]). Adjuvant mitotane therapy was administered to 38  patients 
(38.8%): 18 Italian and 20 German patients, respectively; the remaining 54 patients (55.1%) with 
non metastatic disease did not receive any postoperative treatment. The median follow-up was 66.3 
months in all patients, being 80 months and 62.8 months in the Italian and German cohorts, 
respectively. Among  patients with stage II-III disease, 64 (65.3%)  developed disease recurrence, 
29 of the Italian series (67.4%) and 35 of the German series (74.5%). Among them, 30 were treated 
with chemotherapy; streptozotocyn in 8 patients, EDP (Etoposide, Doxorubicin, Cisplatin) in 22 
patients. Both streptozotocyn and EDP were administered in association with mitotane.  Overall 51 
patients (52.0%) died of ACC progression: 28 (54.9%) in the Italian series and 23 (48.9%) in the 
German series, respectively.  
 
Relationship between tissue marker expression and patient and tumor characteristics 
As outlined in Table 2, both TOP2A and TS gene expression, dichotomized at the median value, did 
not show any significant relationship with histopathologic features, except for the significant direct 
correlation between TS expression levels and Weiss score. TOP2A and TS expressions were 
significantly directly correlated (p=0.006) and both markers showed a direct relationship with 
RRM1 (p=0.026 and p=0.011 for TOP2A and TS, respectively) but not with ERCC1 (p=0.54 and 
p=0.61 for TOP2A and TS, respectively). 
 
Relationship between marker expression and disease free and overall survival 
In univariate analysis, TS gene expression was not associated with DFS [Hazard Ratio (HR): 0.96, 
95% Confidence Interval (CI): 0.60-1.53, p=0.87] and OS (0.86, 95% CI: 0.49-1.50, p=0.60). High 
TOP2A expression levels were associated with higher risk of disease recurrence but just failing to 
attain statistical significance (HR: 1.49, 95% CI: 0.93-2.37, p =0.09) and was significantly 
associated with a higher risk of death (HR: 1.78, 95% CI: 1.02-3.19, p<0.05). In multivariate 
analysis, however, TOP2A expression failed to be a significant independent prognostic parameter 
either in terms of DFS (HR: 1.18, 95% CI: 0.71-1.98, p=0.51) or OS (HR: 1.61, 95% CI: 0.87-2.98, 
p=0.13). 
 
 
Predictive role of TOP2A and TS expression for the efficacy of adjuvant mitotane  
As previously reported, in this series mitotane-treated patients had a longer median DFS than 
untreated patients (22.5 months [95% CI, 1.8–43.1] versus 13.2 months [95% CI, 6.2–20.2], HR, 
0.70 [95% CI, 0.43–1.16; P= 0.17]), and longer median OS (154 months [95%CI, 65.1–242.9] 
versus 53 months [95% CI, 22.6–83.4], HR 0.63 [95% CI, 0.34–1.16; P=0.14]). 
The prognostic effect of mitotane administration was assessed stratifying the patients according to 
marker expression (dichotomised at the median value). As shown in Figure 1, no different effect of 
mitotane treatment was observed in terms of DFS in patients with high versus low TOP2A and TS 
expression. 
 
Predictive role of marker expression of EDP + mitotane activity 
Among the 26 ACC patients who received first line EDP-M for metastatic disease, four (15%) 
achieved a partial response (PR), nine (35%) stable disease (SD) and 13 (50%) experienced 
progressive disease (PD) after 2 or 3 cycles. 
The clinical benefit (SD or PR) of EDP-M was directly associated with TOP2A expression: 12 
SD/PR out of 17 (71%) patients in high TOP2A group as opposed to 1/9 (11%) in low TOP2A 
group (p=0.0039) (Figure 2a). Stratifying patients according to TS expression,  a SD/PR was 
observed in 9/13 (69%) patients with high gene expression and 4/13 (31%) patients with low TS 
expression, respectively (p=0.049) (Figure 2b). EDP-M administration was associated with longer 
time to progression (TTP) in patients with high TOP2A as opposed to those with low TOP2A 
(p=0.038)  (Figure 3), while no difference in terms of TTP after EDP-M was observed stratifying 
patients according to TS (data not shown).     
Neither ERCC1 nor RRM1 correlated with a clinical benefit of the therapy: SD/PR in 8/15 (53%) 
versus 5/11 (45%) in high and low ERCC1 expressing tumors (p=0.69) (Figure 2c); SD/PR in 7/16 
(44%) versus 6/10 (60%) in high and low RRM1 expressing tumors, respectively (p=0.42) (Figure 
2d).  No difference in term of TTP was observed stratifying patients according to both RRM1 and 
ERCC1 expression (data not shown). 
 
Discussion 
TOP2A and TS have been shown to play a prognostic role in several cancers, such as colorectal, 
esophageal, breast, prostate, pancreatic, lung, and other cancers [23-37]. At the best of our 
knowledge, the prognostic role of these two markers has never been explored in ACC.  
In this study, we have measured the mRNA expressions of TOP2A and TS in a relatively large 
series of 98 ACC patients, considering the extreme rarity of this tumor. 
The results showed that TS expression is not prognostic in ACC while TOP2A expression in 
univariate analysis showed a significant correlation with a worse OS although failing to be 
significantly associated with DFS. In multivariate analysis, after adjusting for prognostic factors 
including mitotic index, TOP2A expression failed to be a significant independent prognostic 
parameter. TOP2A is a marker of cell proliferation [38] and the direct correlation of this enzyme 
expression with the mitotic count (although not significant) could account for its failure to be an 
independent prognostic parameter. 
As mentioned in the introduction, both TOP2A and TS are also well known predictors of  
chemotherapy efficacy. In our series, high TOP2A expression in primary ACC was significantly 
associated with responsiveness to EDP-M and increased TTP in metastatic patients.  TOP2A is a 
notorious predictor of efficacy to anthracycline and topoisomerase inhibitors in several tumors, but 
not to cisplatin. However, cisplatin is the reference cytotoxic drug in ACC and it is actually 
unknown whether EDP is more efficacious than cisplatin alone since no randomized studies have 
been conducted. In our opinion, these data suggest the importance of adriamycin and etoposide in 
the EDP scheme, particularly if TOP2A is highly expressed.  
Also TS showed a direct relationship with the disease response of EDP-M, although with a lesser 
magnitude than TOP2A, but not with TTP. Since fluoropyrimidines are not included in the EDP-M 
regimen, the direct relationship of TS with TOP2A may explain the association of this marker 
expression with EDP-M activity. 
In this small series, both RRM1 and ERCC1 failed to be associated with EDP-M activity, this is an 
expected finding for RRM1 since this marker was repeatedly found to be predictive of gemcitabine 
efficacy, but not for ERCC1 that is a predictive factor of cisplatin efficacy in non small cell lung 
cancer [39]. In ACC patients, tissue ERCC1 assessed by immunohistochemistry was associated 
with efficacy of cisplatin containing regimens in one study [40] but not confirmed in another series 
[41].      
In this paper we also explored the potential role of TOP2A and TS for mitotane efficacy in adjuvant 
setting. Although very recently sterol-O-acyl-transferase 1 (SOAT1) was identified as a key 
intracellular target of mitotane (41), the identification of a possible association between mitotane 
efficacy with a biological parameter in an explorative analysis, would be very useful to understand 
the mechanisms of sensitivity and resistance of ACC to this drug. 
Both TOP2A and TS failed to have a predictive role for adjuvant mitotane efficacy; however the 
difference in the DFS curves of adjuvant mitotane versus follow-up only in low versus high TS 
expressing ACC, although not significant, does not exclude the potential role of this marker of 
mitotane efficacy. 
    
In conclusion, the predictive role of TOP2A expression with the efficacy of EDP-M is new and of 
potential clinical relevance.  EDP is a toxic regimen and this observation, if confirmed, suggests the 
potential importance of adding adriamycin and etoposide to cisplatin in highly expressing TOP2A 
tumors, while these 2 drugs might be unhelpful in low TOP2A expressing ACC.  
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